System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Kausik K Ray is an expert in Cardiology at Imperial College Healthcare NHS Trust (United Kingdom). As of October 2026, ScienceLeadR ranks Kausik K Ray in the top 1% of experts worldwide for Hypercholesterolemia, Dyslipidemias and Lipid Metabolism Disorders. Kausik K Ray has authored 664 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 1 of them ongoing. SLR score: 3,892 (community average: 125). How the SLR is computed.

LeadR Profile

Kausik K Ray Imperial College Healthcare NHS Trust United Kingdom
3 892 ScienceLeadR Reputation 3892

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Endocrinology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Imperial College London

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 664

Citations

Citations: 86 463 1st author: 128 Last author: 169 Unique author: 13

Main journals

Eur Heart J 87
Atherosclerosis 59
J Am Coll Cardiol 52
Circulation 42
Eur J Prev Cardiol 22

Best Journals

Eur Heart J 38
N Engl J Med 16
JAMA 14

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Using gap to goal to guide treatment escalation: lessons from VICTORION-Challenge and beyond.
PMID 42670189 — cardiology, therapeutics		Eur Heart J Top journal20260
A Marathon, Not a Sprint-AMUNDSEN and LDL-C Lowering After Myocardial Infarction.
PMID 42666085 — myocardial infarction, marathon running		JAMA Top journal20261
ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey.
PMID 42666091 — heart diseases, heart, cardiac rehabilitation, rehabilitation, cardiology, secondary prevention, coronary disease, risk factors		Eur Heart J Top journal20261
Real-world efficacy of inclisiran: data from a tertiary lipid clinic.
PMID 42568963 — cholesterol, ldl, cardiovascular diseases, rna, small interfering, cholesterol, therapeutics		Br J Cardiol20260
Association of Cancer Incidence and Cancer-Related Mortality with Statin Therapy, Ezetimibe, and Statin-Ezetimibe Combination - A Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials.
PMID 42520400 — mortality, ezetimibe, incidence, cardiovascular diseases, neoplasms, network meta-analysis, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors		Eur J Prev Cardiol20260

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 19
N/A 6
Phase 2 5
Phase 4 5
Phase 1 2

By status:

Completed 31
Terminated 3
Recruiting 2
Active not recruiting 1

By type:

Interventional 33
Observational 4

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 3
multicentricup10 30

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib Ezetimibe on Coronary Plaque
NCT06305559 — ezetimibe, hyperlipidemias, coronary artery disease, cardiovascular diseases, angiography, arteries, therapeutics, plaque, atherosclerotic, computed tomography angiography, lipids		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS